# One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study

> **NCT03662919** · — · COMPLETED · sponsor: **Biogen** · enrollment: 2274 (actual)

## Conditions studied

- Arthritis, Rheumatoid
- Spondylitis, Ankylosing
- Arthritis, Psoriatic
- Crohn's Disease
- Colitis, Ulcerative

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Adalimumab

## Key facts

- **NCT ID:** NCT03662919
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-02
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 2274 (ACTUAL)
- **Last updated:** 2022-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03662919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03662919, "One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03662919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*